With an increasing number of COVID-19 vaccines becoming available, the end of the pandemic is now in sight, but even with efforts to scale up production the supply of vaccines will influence the speed of vaccination. As a result, careful vaccine allocation is needed to maximize social and economic benefits across the U.S. Multiple frameworks have recently been developed to guide vaccine allocation, including one led by our team at CRA and the Center for Global Health Innovation (CGHI) Vaccine Economics and Equity Group (VEEG).1 As we discuss in PM360, this new framework offers guidelines for COVID-19 vaccine allocation under conditions of scarcity that considers core public health and ethical principles in the context of optimal benefit to the U.S. economy.
Dr. Gregory Bell named Exceptional Expert in Power Players report on International Arbitration
Financier Worldwide Magazine featured CRA’s Dr. Gregory Bell as an Exceptional Expert in the Power Players report on International Arbitration.